Business · 25/05/2007Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for KDR 401 and 403 PACEMAKERS
Summary
The US Food and Drug Administration (FDA) has officially confirmed the review period for patent extension for KDR 401 and 403 PACEMAKERS, a medical device, in accordance with federal regulations.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →